Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia 이형접합 가족성 고콜레스테롤혈증 치료를 위한 인클리시란

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

이형접합 가족성 고콜레스테롤혈증 치료를 위한 인클리시란

Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin–kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but require administration every 2 to 4 weeks. In a phase 2 trial, a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia.